I-MAB (IMAB) EBITDA Margin % : -8,665.86% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. I-MAB's EBITDA for the six months ended in Dec. 2023 was $-96.97 Mil. I-MAB's Revenue for the six months ended in Dec. 2023 was $1.12 Mil. Therefore, I-MAB's EBITDA margin for the quarter that ended in Dec. 2023 was -8,665.86%.

I-MAB EBITDA Margin % Historical Data

The historical data trend for I-MAB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB EBITDA Margin % Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-4,778.14

32.88

-2,613.57

1,102.54

-5,108.21

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial								-1,840.11	-1,953.68	522.85	-3,930.09	-8,665.86

Competitive Comparison of I-MAB's EBITDA Margin %

For the Biotechnology subindustry, I-MAB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where I-MAB's EBITDA Margin % falls into.

I-MAB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

I-MAB's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-197.79	/	3.872
	=	-5,108.21 %

I-MAB's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-96.971	/	1.119
	=	-8,665.86 %

I-MAB (NAS:IMAB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

I-MAB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of I-MAB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.